Founder, CEO and Chairman

Chief Financial Officer

Gossamer Bio granted option to acquire Respira

Respira Therapeutics Collaborates with Gossamer Bio to Fast-Track Development of RT234 for Pulmonary Hypertension

Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension

Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital

Join Our Talent Community

Gossamer Bio is a clinical-stage biopharmaceutical company focused on developing investigational drug products for rare diseases. They are inviting individuals interested in potential job opportunities to join their Talent Community by submitting their resumes for future positions.

Sign up with Google

Sign in with Google